VEGFA and neoplasm: Additional therapeutic agents that disrupt functional tumour angiogenesis have been developed to target tumours that are inherently resistant to anti-VEGF therapy or become resistant during the course of therapy (Noguera-Troise et al, 2006; Ridgway et al, 2006; Pan et al, 2007; Caunt et al, 2008).